Literature DB >> 34331706

"Real world" eligibility for aducanumab.

Marco Canevelli1,2, Paolo Dionigi Rossi3, Paolo Astrone4, Ernesto Consorti5, Nicola Vanacore2, Matteo Cesari6,7.   

Abstract

Year:  2021        PMID： 34331706     DOI： 10.1111/jgs.17390

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  3 in total

1.  The new therapy for Alzheimer's disease: from a hope for a few to a false hope?

Authors:  Stefania Orini; Cristina Geroldi; Orazio Zanetti
Journal:  Aging Clin Exp Res       Date:  2022-05-19       Impact factor: 3.636

2.  "Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.

Authors:  Alessandro Padovani; Salvatore Caratozzolo; Luca Rozzini; Andrea Pilotto; Alberto Benussi; Gioacchino Tedeschi
Journal:  J Am Geriatr Soc       Date:  2021-11-09       Impact factor: 7.538

3.  Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria.

Authors:  Zara Togher; Helena Dolphin; Caoimh Russell; Marie Ryan; Séan P Kennelly; Séan O'Dowd
Journal:  Int J Geriatr Psychiatry       Date:  2022-08       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.